| Project/Area Number |
22659172
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | National Center of Neurology and Psychiatry |
|---|
Principal Investigator |
NAGAI Yoshitaka 独立行政法人国立精神・神経医療研究センター, 神経研究所疾病研究第四部, 室長 (60335354)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SUZUKI Mari (独)国立精神・神経医療研究センター, 神経研究所疾病研究第四部, 外来研究員 (20455405)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,300,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥600,000)
Fiscal Year 2011: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2010: ¥700,000 (Direct Cost: ¥700,000)
|
|---|
| Keywords | 神経変性疾患 / ポリグルタミン病 / 蛋白質 / 凝集 / アミロイド / 治療薬 / ペプチド / 分子デザイン / 神経科学 / 脳神経疾患 |
|---|
| Research Abstract |
Toward developing a drug for the polyglutamine(polyQ) neurodegenerative diseases by molecular design of chemical analogues of the aggregation inhibitor peptide QBP1, 1) we identified the minimal sequence of QBP1(WKWWPGIF) and five essential residues within QBP1 for its activity. We also found a tight correlation between their aggregation inhibitory activity and polyQ binding affinity. 2) We further showed by NMR analyses that the polyQ stretch does not adopt an ordered structure in the QBP1-polyQ complex.
|
